



1635 not here
3/16/99

GAO 1635

AMENDMENT TRANSMITTAL LETTER				Docket Number (Optional) MIV-071.10			
Application Number 09/016,869	Filing Date January 30, 1998	Examiner Not yet assigned	Group Art Unit 1635 DAVE Nguyen				
Invention Title CELL-CYCLE REGULATORY PROTEINS, AND USES RELATED THERETO							
TO THE ASSISTANT COMMISSIONER FOR PATENTS Transmitted herewith is a preliminary amendment in the above-identified application. <ul style="list-style-type: none"> <input type="checkbox"/> Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted. <input type="checkbox"/> A Verified Statement to Establish Small Entity Status under 37 CFR 1.27 is enclosed. <input checked="" type="checkbox"/> No additional fee is required. <input type="checkbox"/> The fee has been calculated as shown below: 							
CLAIMS AS AMENDED							
		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT NUMBER EXTRA	12:CLM/12/10/21 RATE	FEE
TOTAL CLAIMS		27	minus	57	0	x \$22	- 0 -
INDEPENDENT CLAIMS		4	minus	14	0	x \$80	- 0 -
MULTIPLE DEPENDENT CLAIM ADDED						\$260	- 0 -
						TOTAL	- 0 -
If applicant has small entity status under 37 CFR 1.9 and 1.27, then divide total fee by 2, and enter amount here.						SMALL ENTITY TOTAL	N/A
<ul style="list-style-type: none"> * If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the highest number previously paid for IN THIS SPACE is less than 20, enter "20". *** If the highest number previously paid for IN THIS SPACE is less than 3, enter "3". <p>The "highest number previously paid for" (total or independent) is the highest number found in the appropriate box in column 1.</p> <ul style="list-style-type: none"> <input type="checkbox"/> Please charge Deposit Account Number 06-1448 in the amount of \$_____ A duplicate copy of this sheet is enclosed. <input type="checkbox"/> A check in the amount of \$_____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to credit any overpayment or charge any deficiencies to our Deposit Account Number 06-1448. A duplicate copy of this sheet is enclosed. 							
<u>Anita Varma</u> Anita Varma Reg. No. 43,221 <u>12/3/98</u> Date		<div style="border: 1px solid black; padding: 5px; text-align: center;"> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on December 3, 1998.</p> <p><i>Ariel I. Collazo</i></p> </div>					



Pre Andt
7/10/98
Agenda

PATENT
Attorney Docket No MIV 071.10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
David BEACH et al.)
Serial No.: 09/016,869) Group Art Unit: 1635
Filed: January 30, 1998)
For: *Cell-Cycle Regulatory Proteins, and Uses*) Examiner: not yet assigned
Related Thereto)

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
DEC 6 1998
MIV 071.10
21

CERTIFICATE MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 dated December 3, 1998.

December 3, 1998

Date of Signature
and of Mail Deposit


Ariel I. Collazo

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Applicants respectfully request entry of this preliminary amendment before examination of the claims on the merits. Kindly amend the specification as follows:

IN THE CLAIMS

Please cancel claims 2-9 and 12-57, and add the following new claims:

~~58. An isolated antibody, or fragment thereof, specifically immunoreactive with a cell cycle regulatory (CCR) protein, wherein said protein comprises at least four ankyrin-repeats and specifically binds to a cyclin-dependant kinase.~~

Sub H 16
7/10/98